SCHEMBL1376469

SCHEMBL1376469

CCCNC(=O)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9468832 0.97
SCHEMBL19446214 0.91 MCL1 (0.45)
SCHEMBL22420468 0.91 MCL1 (0.45)
SCHEMBL24864680 0.86 PAOX (0.45)
SCHEMBL3618453 0.85
SCHEMBL993169 0.83 CASP2 (0.63)
Hydrochloric Acid SCHEMBL28987434 0.83 CASP2 (0.52)
SCHEMBL3074874 0.83 CA2 (0.44)
SCHEMBL3172352 0.81 CASP2 (0.67)
SCHEMBL22776495 0.81 CASP2 (0.67)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4805909-B2 2011-11-02 JP claimed
US-20100087440-A1 Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use EXELIXIS, INC. 2010-04-08 US claimed
EP-2139483-A2 COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER Exelixis, Inc. (US) 2010-01-06 EP claimed
WO-2008127594-A2 COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS, INC. (US) 2008-10-23 WO claimed
EP-1931645-A2 N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS Exelixis, Inc. (US) 2008-06-18 EP claimed
EP-1809275-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-07-25 EP claimed
WO-2007044729-A2 N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS EXELIXIS, INC. (US) 2007-04-19 WO claimed
WO-2006044707-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-04-27 WO claimed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP claimed
EP-1339687-A1 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS Bayer Aktiengesellschaft (DE) 2003-09-03 EP claimed
US-20030139427-A1 Bicyclic pyrimidinyl derivatives and methods of use thereof OSI PHARMACEUTICALS INC. 2003-07-24 US claimed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO claimed
WO-2002044153-A1 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2002-06-06 WO claimed
EP-0632039-B1 2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-carbapenem derivatives WYETH LEDERLE JAPAN LTD (JP) 2002-01-30 EP claimed
US-5534510-A ORALLY ADMINISTRABLE THIENAMYCIN ANTIBIOTICS; BETA-LACTAMASE INHIBITORS LEDERLE (JAPAN), LTD. (JP) 1996-07-09 US claimed
EP-0007597-B1 N-LOWERALKYL-GLYCINAMIDES AND SARCOSINE ANHYDRIDE AND THEIR MIXTURES WITH KNOWN TUMOR-INHIBITING COMPOUNDS, SARCOSIN FOR USE IN THE TREATMENT OF TUMORS, MEDICAMENTS CONTAINING THESE COMPOUND AND PROCESSES FOR THEIR PREPARATION Stiftung Deutsches Krebsforschungszentrum (DE) 1985-01-16 EP claimed
US-20250346567-A1 SUBSTITUTED PYRIDINE AND PHENYL COMPOUNDS PFIZER INC. (US) 2025-11-13 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-4127584-A 2,3-Substituted-1,2,5-thiadiazolium salt antimicrobials MERCK & CO., INC. (US) 1978-11-28 US disclosed
US-4094986-A BACTERICIDES, FUNGICIDES M. S. & D. (I.A.) CORP. (US) 1978-06-13 US disclosed